Why Is HUTCHMED CHINA LTD ADR (HCM) Stock Up Today?

HCM stock is up 14.62% at $13.80 in today’s session, driven by a major licensing agreement with GSK for a novel cancer therapy. The deal, covering HMPL-A830, includes upfront and milestone payments totaling up to $1.295 billion. The stock opened with a 13.0% gap up and has traded in a $13.33 to $13.89 range since the market opened.

What Happened

Hutchmed announced an exclusive licensing agreement with a GSK subsidiary for HMPL-A830, a first-in-class KRAS/EGFR antibody conjugate therapy for cancer. Under the deal, Hutchmed will lead the global Phase I development, expected to start in the second half of 2026. GSK will manage all subsequent development and commercialization activities outside of Mainland China, Hong Kong, Macau, and Taiwan. The upfront payment of $110 million is expected to provide immediate cash flow to the company. This partnership represents a significant validation of Hutchmed’s pipeline and expands its access to global oncology markets.

What The Data Shows

The stock opened at $13.60, reflecting a strong pre-market reaction to the news. Trading has since moved between $13.33 and $13.89, with the last print at $13.80. Volume has been light so far at 0.0M shares, which is 0.3 times the 3-month average. The stock has been volatile in recent weeks, having fallen 4.7% over the last 8 sessions from $12.63 to $12.04 before today’s gap up. The 52-week high of $18.30 remains out of reach, but the stock has printed five fresh 52-week highs earlier this year. With a market cap of $2.1B, a P/E ratio of 596.3, and a beta of 0.44, the stock remains a speculative play with high growth expectations.

What To Watch

The next key event for investors will be the start of the Phase I trial in the second half of 2026. Coverage breadth is currently at five stories from five sources in the last 36 hours, indicating growing interest in the stock.